| Journal | Immunopharmacology and immunotoxicology |
| Study Type | Clinical Study |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
Inflammation is an evolutionarily conserved adaptive process essential for host defense against harmful stimuli, aimed at restoring homeostasis. However, exacerbated or dysregulated responses are associated with the progression of several autoimmune and chronic inflammatory diseases, representing a significant clinical challenge. The endocannabinoid system has been described as an important immunomodulatory pathway in which synthetic cannabinoids exert immunosuppressive effects, providing novel therapeutic targets. Aryl-Cyclohexanone (AD) has previously demonstrated anti-inflammatory properties in both Herein we aimed to investigate its immunomodulatory profile In J774 macrophages, AD treatment preserved cell viability, reduced nitric oxide metabolites production, normalized apoptotic events, and enhanced phagocytosis. Additionally, decreased Toll-like receptor 4 and increased mannose receptor (CD206) expressions were observed, along with a significant reduction in pro-inflammatory cyt
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.
